

MOVING TOWARDS SUSTAINED PROTECTION WITH FVIII IN THE NON-HAEMOPHILIA RANGE

Monday 23 June 2025

13:45–14:30

Presentation Theatre, Room 1

isth
International Society on
Thrombosis and Haemostasis



Join our expert faculty in this
Presentation Theatre on **ALTUVOCT**[®]▼
at ISTH 2025, covering its unique molecular
identity, its impact on the treatment landscape
and practical insights on its use in clinical practice

Faculty: Niamh O'Connell, Ireland and Víctor Jiménez Yuste, Spain

 **sobi**

This material is not intended for viewing or use by HCPs licensed in the US or Canada, nor anywhere in North America, South America, Japan, or Taiwan. Please refer to Sobi employees for information. Efanesoctocog alfa is approved in the EU under Centralized Authorisation EMEA/H/C/005968/0000, with the EU decision number (2024)4303 17 June 2024. Local authorisation and product availability may differ by country.

Please click on this link for more information: [Altuvoc | European Medicines Agency \(EMA\)](#)

This promotional presentation theater is intended for healthcare professionals. Produced and paid for by Sobi™.

©2025 Swedish Orphan Biovitrum AB (publ) – all rights reserved

Swedish Orphan Biovitrum AB (publ). SE-112 76 Stockholm, Sweden. www.sobi.com

PP-27286. Date of preparation: April 2025

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any Adverse Event (AE) including any suspected adverse drug reactions (ADRs). Must be reported to Swedish Orphan Biovitrum AB by email: drugsafety@sobi.com